Home infusion therapy statistics at a glance
Home infusion therapy has a clear scale story in the latest CMS monitoring data: the service is used consistently, but the supply side and drug mix are concentrated enough that a few categories and suppliers carry a large share of the volume (CMS HIT Monitoring Report Feb 2026; CMS Home IVIG Monitoring Report Mar 2026).
Fast facts:
- CMS reported a quarterly average of 6,991 HIT service visits from Q1 2023 through Q2 2025 (CMS HIT Monitoring Report Feb 2026).
- CMS reported 28,422 total HIT service visits in Q3 2024 through Q2 2025, including 1,025 initial visits and 27,397 subsequent visits (CMS HIT Monitoring Report Feb 2026).
- CMS reported 33,531 home IVIG visits in Q3 2024 through Q2 2025, with 8,792 home IVIG visits in Q2 2025 alone (CMS Home IVIG Monitoring Report Mar 2026).
- CMS reported 7 of 73 HIT supplier organizations provided 54.0% of HIT service visits in the last 12 months ending June 30, 2025 (CMS HIT Monitoring Report Feb 2026).
- CMS set 2026 national HIT rates from $190.22 to $388.89 depending on the billing code (CMS CY 2026 National Home Infusion Therapy Services Rates).
Table of contents
- Home infusion therapy statistics overview
- Service visit volume and trend data
- What the category breakdown shows
- Supplier concentration and market structure
- Home IVIG statistics and product mix
- 2026 national rate benchmarks
- How to read these home infusion therapy statistics
Home infusion therapy statistics overview
The strongest pattern in the CMS data is not just volume. It is the combination of recurring utilization, a concentrated supplier base, and a narrow set of drugs that account for a large share of visits across home infusion therapy and home IVIG (CMS HIT Monitoring Report Feb 2026; CMS Home IVIG Monitoring Report Mar 2026).
Why it matters: if you are trying to understand home infusion therapy statistics as an operational market rather than a single-service metric, the important signals are frequency, concentration, and code-level mix. The supplied CMS figures show all three at once.
A useful way to read the data is to separate the market into three layers:
- overall HIT service activity,
- service category mix,
- home IVIG utilization and drug concentration.
That structure makes the numbers easier to compare and keeps the biggest changes visible without turning the dataset into a flat list.
Service visit volume and trend data
CMS reported 6,991 average quarterly HIT service visits from Q1 2023 through Q2 2025 (CMS HIT Monitoring Report Feb 2026). That average sits close to the actual endpoints CMS reported for the period, with 7,400 HIT service visits in Q1 2023 and 7,365 HIT service visits in Q2 2025 (CMS HIT Monitoring Report Feb 2026).
That shape suggests a market that is not expanding in a straight line, but is still operating at a substantial recurring volume. The more informative point is the mix of first-time and follow-up activity.
Big number: subsequent visits dominate
CMS reported 1,025 initial HIT service visits and 27,397 subsequent HIT service visits in Q3 2024 through Q2 2025, for 28,422 total HIT service visits (CMS HIT Monitoring Report Feb 2026).
That means subsequent visits accounted for the overwhelming majority of activity in that period. In practical terms, the data points to an established service pattern rather than a mostly one-time utilization model.
Visit volume by supplier band
CMS also broke HIT visits into supplier bands for Q3 2024 through Q2 2025. The bands show how visit volume scales across organizations of different sizes.
| Supplier band | Organizations | HIT visits |
|---|---|---|
| 1 to 99 visits | 46 | 1,561 |
| 100 to 499 visits | 21 | 5,595 |
| 500 to 999 visits | 6 | 4,519 |
| 1,000 to 1,499 visits | 1 | 1,385 |
| 1,500+ visits | 7 | 15,362 |
These counts show an obvious skew toward the upper end of the market. Only 7 supplier organizations were in the 1,500+ visit band, yet they produced 15,362 visits in the period (CMS HIT Monitoring Report Feb 2026).
What the category breakdown shows
CMS split HIT activity into three categories for Q3 2024 through Q2 2025, and the mix is balanced enough to matter.
Category 1, 2, and 3 totals
| HIT category | Initial visits | Subsequent visits | Total visits |
|---|---|---|---|
| Category 1 | 268 | 12,383 | 12,651 |
| Category 2 | 488 | 10,011 | 10,499 |
| Category 3 | 269 | 5,003 | 5,272 |
Category 1 had the largest total at 12,651 visits, followed by Category 2 at 10,499, and Category 3 at 5,272 (CMS HIT Monitoring Report Feb 2026).
A few things stand out immediately:
- Category 1 led in both initial and total visits.
- Category 2 was close behind, with a large subsequent-visit base.
- Category 3 was materially smaller, but still represented a meaningful slice of overall volume.
The category totals matter because they show that home infusion therapy statistics are not driven by a single service type. Instead, the category mix is broad enough that workflow, staffing, and supply planning all have to account for multiple utilization profiles.
Drug-level examples within the categories
CMS also listed specific drugs tied to category activity in Q3 2024 through Q2 2025.
For Category 1, the top listed HIT visits were:
- 10,467 for milrinone lactate (J2260) (CMS HIT Monitoring Report Feb 2026)
- 1,360 for dobutamine HCl (J1250) (CMS HIT Monitoring Report Feb 2026)
- 237 for treprostinil (J3285) (CMS HIT Monitoring Report Feb 2026)
For Category 2, the listed HIT visits were:
- 4,466 for Hizentra (J1559 JB) (CMS HIT Monitoring Report Feb 2026)
- 2,372 for Cuvitru (J1555 JB) (CMS HIT Monitoring Report Feb 2026)
- 1,494 for hyaluronidase (J1575 JB) (CMS HIT Monitoring Report Feb 2026)
For Category 3, CMS reported 4,908 visits for fluorouracil (J9190) (CMS HIT Monitoring Report Feb 2026).
These figures are useful because they show the category mix is not abstract. It is tied to a small number of named products that dominate portions of the service mix.
Supplier concentration and market structure
One of the most important home infusion therapy statistics in the dataset is concentration at the supplier level.
CMS reported 69 HIT supplier organizations in Q1 2023 and 61 HIT supplier organizations in Q2 2025 (CMS HIT Monitoring Report Feb 2026). That is a modest decline in the number of suppliers across the period.
CMS also reported that 7 of 73 HIT supplier organizations provided 54.0% of HIT service visits in the 12 months ending June 30, 2025 (CMS HIT Monitoring Report Feb 2026).
That is a strong concentration signal. The supply base is not evenly distributed; a small top tier controls a majority of service volume.
What the concentration pattern implies
The supplier-band data and the top-supplier share tell the same story from different angles:
- a long tail of low-volume organizations exists,
- a mid-tier handles a substantial share of visits,
- the top end is disproportionately important to total volume.
The same concentration appears in the supplier count by band. The 1,500+ band had only 7 organizations, but it held 15,362 visits, which was more than any other band by a wide margin (CMS HIT Monitoring Report Feb 2026).
For planning purposes, that structure means the market can look stable at the aggregate level while still being vulnerable to changes in a relatively small number of high-volume suppliers.
Drug suppliers are also expanding
CMS reported 289 HIT drug supplier organizations in Q1 2023 and 325 HIT drug supplier organizations in Q2 2025 (CMS HIT Monitoring Report Feb 2026).
That is a different trend from the HIT service supplier count. Drug supplier participation increased even as the HIT supplier count declined. The dataset does not explain why, but it does show that supply-side change is not uniform across the market.
Home IVIG statistics and product mix
Home IVIG is one of the clearest comparison points in the dataset because CMS provided both visit counts and beneficiary counts over time.
CMS reported 5,007 home IVIG visits in Q1 2023, 5,777 in Q4 2023, and 8,792 in Q2 2025 (CMS Home IVIG Monitoring Report Mar 2026).
That progression shows a notable increase across the period. CMS also reported that home IVIG visits increased by 3,015, or 52.2%, from Q4 2023 to Q2 2025 (CMS Home IVIG Monitoring Report Mar 2026).
Home IVIG at a glance
- 92 DME suppliers provided home IVIG visits in Q4 2023 (CMS Home IVIG Monitoring Report Mar 2026).
- That number increased to 137 in Q1 2024 and 161 in Q2 2025 (CMS Home IVIG Monitoring Report Mar 2026).
- CMS reported 36,119 beneficiaries receiving home IVIG drugs in Q1 2023 and 45,040 beneficiaries in Q2 2025 (CMS Home IVIG Monitoring Report Mar 2026).
- CMS reported 3,329 beneficiaries with PIDD claims in Q1 2023 and 3,786 in Q2 2025 (CMS Home IVIG Monitoring Report Mar 2026).
The rise in supplier participation and the rise in beneficiary counts both support the same directional reading: home IVIG activity broadened over the period.
Home IVIG product concentration
CMS reported a total of 33,531 home IVIG visits for Q3 2024 through Q2 2025 (CMS Home IVIG Monitoring Report Mar 2026).
Within that total, the largest named products were:
- 8,288 visits for Gamunex (J1561), or 24.7% (CMS Home IVIG Monitoring Report Mar 2026)
- 7,932 visits for Gammagard liquid (J1569), or 23.7% (CMS Home IVIG Monitoring Report Mar 2026)
- 3,899 visits for Privigen (J1459), or 11.6% (CMS Home IVIG Monitoring Report Mar 2026)
- 3,299 visits for Panzyga (J1576), or 9.8% (CMS Home IVIG Monitoring Report Mar 2026)
- 3,070 visits for Gammaplex (J1557), or 9.2% (CMS Home IVIG Monitoring Report Mar 2026)
- 1,898 visits for Bivigam (J1556), or 5.7% (CMS Home IVIG Monitoring Report Mar 2026)
- 1,765 visits for Octagam (J1568), or 5.3% (CMS Home IVIG Monitoring Report Mar 2026)
- 1,360 visits for Asceniv (J1554), or 4.1% (CMS Home IVIG Monitoring Report Mar 2026)
- 1,227 visits for IVIG, NOS lyophilized (J1566), or 3.7% (CMS Home IVIG Monitoring Report Mar 2026)
- 630 visits for Alyglo (J1552), or 1.9% (CMS Home IVIG Monitoring Report Mar 2026)
- 150 visits for IVIG, NOS non-lyophilized (J1599), or 0.4% (CMS Home IVIG Monitoring Report Mar 2026)
A compact view of the biggest products makes the mix easier to scan.
| Home IVIG product | Visits | Share |
|---|---|---|
| Gamunex (J1561) | 8,288 | 24.7% |
| Gammagard liquid (J1569) | 7,932 | 23.7% |
| Privigen (J1459) | 3,899 | 11.6% |
| Panzyga (J1576) | 3,299 | 9.8% |
| Gammaplex (J1557) | 3,070 | 9.2% |
The top two products alone accounted for nearly half of all home IVIG visits in the period, which is a strong concentration pattern even before the rest of the list is considered (CMS Home IVIG Monitoring Report Mar 2026).
2026 national rate benchmarks
CMS set the CY 2026 national HIT rates at the following levels:
- G0068: $190.22 (CMS CY 2026 National Home Infusion Therapy Services Rates)
- G0069: $257.04 (CMS CY 2026 National Home Infusion Therapy Services Rates)
- G0070: $319.76 (CMS CY 2026 National Home Infusion Therapy Services Rates)
- G0088: $231.36 (CMS CY 2026 National Home Infusion Therapy Services Rates)
- G0089: $312.60 (CMS CY 2026 National Home Infusion Therapy Services Rates)
- G0090: $388.89 (CMS CY 2026 National Home Infusion Therapy Services Rates)
| Code | 2026 national rate |
|---|---|
| G0068 | $190.22 |
| G0069 | $257.04 |
| G0070 | $319.76 |
| G0088 | $231.36 |
| G0089 | $312.60 |
| G0090 | $388.89 |
The range between the lowest and highest listed rate is substantial, which makes code-level billing differences worth watching closely when reading home infusion therapy statistics in a financial context (CMS CY 2026 National Home Infusion Therapy Services Rates).
How to read these home infusion therapy statistics
A clean way to interpret the dataset is to keep four layers separate:
- Activity level: CMS reported a quarterly average of 6,991 HIT service visits, which frames the overall scale of service use (CMS HIT Monitoring Report Feb 2026).
- Visit structure: The ratio of 1,025 initial to 27,397 subsequent visits shows that ongoing care dominates the service pattern (CMS HIT Monitoring Report Feb 2026).
- Market concentration: A small number of supplier organizations accounted for a majority of visits, with 7 of 73 suppliers providing 54.0% of volume (CMS HIT Monitoring Report Feb 2026).
- Product concentration: Both HIT and home IVIG data show that a few drugs account for a large portion of visits, especially in the home IVIG mix (CMS HIT Monitoring Report Feb 2026; CMS Home IVIG Monitoring Report Mar 2026).
The result is a market that looks broad from a category perspective but concentrated from a supplier and product perspective. That combination is the main takeaway from the current CMS home infusion therapy statistics dataset.
If you compare the data points across services, home IVIG stands out for growth in visits and beneficiaries, while the broader HIT market stands out for recurring utilization and supplier concentration. The 2026 rate schedule then adds a pricing layer that is easy to compare code by code when assessing the economics behind the service counts (CMS CY 2026 National Home Infusion Therapy Services Rates).